Pub Date : 2021-09-23DOI: 10.37191/mapsci-2582-385x-3(5)-088
G. Slater
Bone grafting represents an important solution for defects in maxillofacial and orthopaedic surgeries. Ideal properties of a bone graft allow proper integration, enabling cosmetic appeal and mechanical functionality. Whilst current autograft, allograft and xenograft applications do exist and are regularly used clinically, they are associated with numerous solutions, such as availability, disease transmission and donor site morbidity. Synthetic and naturally sourced solutions can avoid these issues, whilst maintaining the ideal bone integrative properties of their autograft counterparts. This case series aims to identify the effectiveness of a natural bone graft substitute, coralline hydroxyapatite, in maxillofacial applications, and demonstrate that coralline hydroxyapatite encourages bone ingrowth for dental defects.
{"title":"Case Series: Use of Coralline Hydroxyapatite Graft In Faciomaxillary Surgery","authors":"G. Slater","doi":"10.37191/mapsci-2582-385x-3(5)-088","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-3(5)-088","url":null,"abstract":"Bone grafting represents an important solution for defects in maxillofacial and orthopaedic surgeries. Ideal properties of a bone graft allow proper integration, enabling cosmetic appeal and mechanical functionality. Whilst current autograft, allograft and xenograft applications do exist and are regularly used clinically, they are associated with numerous solutions, such as availability, disease transmission and donor site morbidity. Synthetic and naturally sourced solutions can avoid these issues, whilst maintaining the ideal bone integrative properties of their autograft counterparts. This case series aims to identify the effectiveness of a natural bone graft substitute, coralline hydroxyapatite, in maxillofacial applications, and demonstrate that coralline hydroxyapatite encourages bone ingrowth for dental defects.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"210 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125489762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-09-07DOI: 10.37191/mapsci-2582-385x-3(6)-089
Farihah Khaliq
Stem cell therapy is an approach to use cells that have the ability of self-renewal and to differentiate into different types of functional cells that are obtained from embryo and other postnatal sources to treat multiple disorders. These cells can be differentiated into different types of stem cells based on their specific characteristics to be totipotent, unipotent, multipotent or pluripotent. As potential therapy, pluripotent stem cells are considered to be the most interesting as they can be differentiated into different type of cells with similar characteristics as embryonic stem cells. Induced pluripotent stem cells (iPSCs) are adult cells that are reprogrammed genetically into stem cells from human fibroblasts through expressing genes and transcription factors at different time intervals. In this review, we will discuss the applications of stem cell therapy using iPSCs technology in treating neurodegenerative disorder such that Alzheimer’s disease (AD), Parkinson’s disease (PD), and Amyotrophic Lateral Sclerosis (ALS). We have also broadly highlighted the significance of pluripotent stem cells in stem cell therapy.
{"title":"Stem Cells in Neurodegenerative Disorders - A broad Overview","authors":"Farihah Khaliq","doi":"10.37191/mapsci-2582-385x-3(6)-089","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-3(6)-089","url":null,"abstract":"Stem cell therapy is an approach to use cells that have the ability of self-renewal and to differentiate into different types of functional cells that are obtained from embryo and other postnatal sources to treat multiple disorders. These cells can be differentiated into different types of stem cells based on their specific characteristics to be totipotent, unipotent, multipotent or pluripotent. As potential therapy, pluripotent stem cells are considered to be the most interesting as they can be differentiated into different type of cells with similar characteristics as embryonic stem cells. Induced pluripotent stem cells (iPSCs) are adult cells that are reprogrammed genetically into stem cells from human fibroblasts through expressing genes and transcription factors at different time intervals. In this review, we will discuss the applications of stem cell therapy using iPSCs technology in treating neurodegenerative disorder such that Alzheimer’s disease (AD), Parkinson’s disease (PD), and Amyotrophic Lateral Sclerosis (ALS). We have also broadly highlighted the significance of pluripotent stem cells in stem cell therapy.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126747718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-08DOI: 10.37191/mapsci-2582-385x-3(5)-086
Nicole Min Qian Pek
Over the past decade, new advancements in stem cell and three-dimensional cell culture technologies have reignited interests in organoid research. The unassuming ‘blobs’ of cells made to mimic organs are revolutionizing human medicine. By utilizing stem cells such as human pluripotent stem cells (hPSCs), a wide variety of organoids can be generated in the lab. hPSC-derived organoids have proven to be powerful tools to model complex human diseases including but not limited to developmental disorders, degenerative diseases, infectious diseases, metabolic diseases, and cancers. Due to their complexities and multi-cellularity, these organoids can better recapitulate sophisticated disease phenotypes when compared to monolayered cells. Diseased organoids can then be easily expanded in vitro for drug discovery or high-throughput therapeutic screening. Organoid transplantation is also currently explored in the field of regenerative medicine. Researchers are now looking towards the generation of ‘next-gen’ organoids that reflect even higher degrees of organ complexities to achieve greater levels of cellular maturity and functionality while still maintaining its relatively simple form. Organoids, undoubtedly, hold tremendous promise in helping us understand and treat a wide array of human diseases.
{"title":"Organoids: Three-Dimensional ‘blobs’ that are Reshaping the Future of Medicine","authors":"Nicole Min Qian Pek","doi":"10.37191/mapsci-2582-385x-3(5)-086","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-3(5)-086","url":null,"abstract":"Over the past decade, new advancements in stem cell and three-dimensional cell culture technologies have reignited interests in organoid research. The unassuming ‘blobs’ of cells made to mimic organs are revolutionizing human medicine. By utilizing stem cells such as human pluripotent stem cells (hPSCs), a wide variety of organoids can be generated in the lab. hPSC-derived organoids have proven to be powerful tools to model complex human diseases including but not limited to developmental disorders, degenerative diseases, infectious diseases, metabolic diseases, and cancers. Due to their complexities and multi-cellularity, these organoids can better recapitulate sophisticated disease phenotypes when compared to monolayered cells. Diseased organoids can then be easily expanded in vitro for drug discovery or high-throughput therapeutic screening. Organoid transplantation is also currently explored in the field of regenerative medicine. Researchers are now looking towards the generation of ‘next-gen’ organoids that reflect even higher degrees of organ complexities to achieve greater levels of cellular maturity and functionality while still maintaining its relatively simple form. Organoids, undoubtedly, hold tremendous promise in helping us understand and treat a wide array of human diseases.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129133122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-07DOI: 10.37191/mapsci-2582-385x-3(5)-085
N. Iqbal
The outbreak of COVID-19 and succeeding lockdown curtailment of routine life activities resulted in a profound effect on healthcare systems, globally. There were difficulties in Outpatient follow-up during this time. Since the start of the lockdowns, the general cardiology clinics have faced challenges of social distancing and safe clinical practices to ensure the safety of healthcare workers and cardiology patients. During the lockdowns, telemedicine gained significance in the healthcare industry. It was utilized to triage patients before allowing them to the emergency department. It also offered help in remote monitoring for isolated patients in high dependency patients in hospitals. The aim of this review was to delve into this important aspect in the current literature on both the direct ramifications due to COVID-19 on clinical practice in cardiology clinics. Challenges to the patients and the healthcare personnel. Measures to have a prudent strategy to cope with all these challenges because of the ways in which containment and social distancing measures have derailed daily life.
{"title":"Cardiology Clinic in COVID-19 Era- Review Article","authors":"N. Iqbal","doi":"10.37191/mapsci-2582-385x-3(5)-085","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-3(5)-085","url":null,"abstract":"The outbreak of COVID-19 and succeeding lockdown curtailment of routine life activities resulted in a profound effect on healthcare systems, globally. There were difficulties in Outpatient follow-up during this time. Since the start of the lockdowns, the general cardiology clinics have faced challenges of social distancing and safe clinical practices to ensure the safety of healthcare workers and cardiology patients. During the lockdowns, telemedicine gained significance in the healthcare industry. It was utilized to triage patients before allowing them to the emergency department. It also offered help in remote monitoring for isolated patients in high dependency patients in hospitals. The aim of this review was to delve into this important aspect in the current literature on both the direct ramifications due to COVID-19 on clinical practice in cardiology clinics. Challenges to the patients and the healthcare personnel. Measures to have a prudent strategy to cope with all these challenges because of the ways in which containment and social distancing measures have derailed daily life.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"103 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131578182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-08-04DOI: 10.37191/mapsci-2582-385x-3(5)-087
G. Daltro
The COVID19 pandemic, originating in China, has spread across the world, with serious proportions in populations and public health. Systemic lesions in those infected generate cascading changes affecting different organs. Osteonecrosis is a bone pathology, of different etiologies, common throughout the world, which directs the hip to a disabling condition. Furthermore, there is a polygenic and multifactorial interaction in its pathophysiology. The objective of this paper is to present the first series of cases of osteonecrosis of the femoral head after infection by SARS-CoV-2 and to discuss the possible pathological mechanisms. This is a sample with a male majority with a mean age of 43.5 years, bilateral involvement of the hip sin 100% of cases, mean time between infection and onset of symptoms was 132.8 days. About 33% had osteonecrosis of the femoral head after a mild infection, 66% were moderate or severe cases that used corticosteroid therapy with a minimum dose of 40mg/day of dexamethasone for an average time of 14.6 days. We believe that the association of hypercoagulability mechanisms inherent to COVID-19, direct cell infection and instituted cortico therapy may be responsible for the high incidence of osteonecrosis in the post-covid syndrome.
{"title":"Osteonecrosis Development Post Covid-19 Infection","authors":"G. Daltro","doi":"10.37191/mapsci-2582-385x-3(5)-087","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-3(5)-087","url":null,"abstract":"The COVID19 pandemic, originating in China, has spread across the world, with serious proportions in populations and public health. Systemic lesions in those infected generate cascading changes affecting different organs. Osteonecrosis is a bone pathology, of different etiologies, common throughout the world, which directs the hip to a disabling condition. Furthermore, there is a polygenic and multifactorial interaction in its pathophysiology. The objective of this paper is to present the first series of cases of osteonecrosis of the femoral head after infection by SARS-CoV-2 and to discuss the possible pathological mechanisms. This is a sample with a male majority with a mean age of 43.5 years, bilateral involvement of the hip sin 100% of cases, mean time between infection and onset of symptoms was 132.8 days. About 33% had osteonecrosis of the femoral head after a mild infection, 66% were moderate or severe cases that used corticosteroid therapy with a minimum dose of 40mg/day of dexamethasone for an average time of 14.6 days. We believe that the association of hypercoagulability mechanisms inherent to COVID-19, direct cell infection and instituted cortico therapy may be responsible for the high incidence of osteonecrosis in the post-covid syndrome.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"574 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130621572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-08DOI: 10.37191/https://doi.org/10.37191/mapsci-2582-385x-3(5)-084
Dr. Stefan Bittmann
A drug used successfully in veterinary medicine to treat mast cell tumors in dogs may be effective against COVID-19 and some other viral diseases in humans, according to laboratory experiments and preclinical studies published in Science 2021 [1]. Coronaviruses also require such enzymes. After entering the cells, their genome is first converted into 2 polyproteins, which must be broken down into smaller units. This task is performed by 2 proteases. This is once the main protease 3CL (also called Mpro or nsp5). The 2nd enzyme is the "papain-like" protease, abbreviated PLpro. Drugs that block one of these enzymes could prevent the viruses from replicating in the cells and thus stop the progression of the infection.
{"title":"Masitinib and Its Role in Inhibiting SARS-CoV-2 Infection","authors":"Dr. Stefan Bittmann","doi":"10.37191/https://doi.org/10.37191/mapsci-2582-385x-3(5)-084","DOIUrl":"https://doi.org/10.37191/https://doi.org/10.37191/mapsci-2582-385x-3(5)-084","url":null,"abstract":"A drug used successfully in veterinary medicine to treat mast cell tumors in dogs may be effective against COVID-19 and some other viral diseases in humans, according to laboratory experiments and preclinical studies published in Science 2021 [1]. Coronaviruses also require such enzymes. After entering the cells, their genome is first converted into 2 polyproteins, which must be broken down into smaller units. This task is performed by 2 proteases. This is once the main protease 3CL (also called Mpro or nsp5). The 2nd enzyme is the \"papain-like\" protease, abbreviated PLpro. Drugs that block one of these enzymes could prevent the viruses from replicating in the cells and thus stop the progression of the infection.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"37 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126894410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-07-01DOI: 10.37191/MAPSCI-2582-385X-3(5)-083
F. Salis
Finding an effective therapy able to slow Neurocognitive Disorder’s (NCD) progression represents an ambitious purpose of biomedical research. In June 2021, the Food and Drug Administration approved Aducanumab for the treatment of Alzheimer’s disease – the most common cause of dementia worldwide [1]. This drug is a monoclonal antibody that would be cause amyloid-β plaques reduction in the brain [2]. Whether its effectiveness will be confirmed or not, the fact remains that the patients that will benefit the most from any treatment are the ones suffering from mild NCD. Mild NCD is a clinically insidious and difficult-to-diagnose disorder, and consequently, the development and the spread of screening methods are necessary to early intercept these subjects.
{"title":"First-level Neurocognitive Screening Tests and Their Application","authors":"F. Salis","doi":"10.37191/MAPSCI-2582-385X-3(5)-083","DOIUrl":"https://doi.org/10.37191/MAPSCI-2582-385X-3(5)-083","url":null,"abstract":"Finding an effective therapy able to slow Neurocognitive Disorder’s (NCD) progression represents an ambitious purpose of biomedical research.\u0000\u0000In June 2021, the Food and Drug Administration approved Aducanumab for the treatment of Alzheimer’s disease – the most common cause of dementia worldwide [1]. This drug is a monoclonal antibody that would be cause amyloid-β plaques reduction in the brain [2]. Whether its effectiveness will be confirmed or not, the fact remains that the patients that will benefit the most from any treatment are the ones suffering from mild NCD. Mild NCD is a clinically insidious and difficult-to-diagnose disorder, and consequently, the development and the spread of screening methods are necessary to early intercept these subjects.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"99 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127158242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-12DOI: 10.37191/mapsci-2582-385x-3(5)-082
Bhasker Banerji
Introduction: Human Mesenchymal Stem Cell has been scientifically accepted as a method of managing Osteoarthritis in the Human knee. They can be derived from Autologous Bone Marrow, Adipose Tissue, and less commonly Synovial Cells. However, Allogenic Human Umbilical Cord derived Mesenchymal Stem Cells has recently generated interest because harvesting it is noninvasive, availability easy, the cells relatively younger, have insignificant antigenic markers. A Clinical Trial of Allogeneic Intraarticular Human Umbilical Cord derived Mesenchymal Stem Cells was conducted to assess their efficacy in Osteo Arthritis Human Knees. Material and Method: The clinical trials were conducted from my clinic at 72 Tagore Town, Allahabad, UP, India from December 2018 to the third week of March 2021. The period of study was between December 2018 to April 2021. FIRST COVID Lockdown in this city was from 22nd of March 2020 to September 2020. The second Lockdown was from April 2021 to May 2021. Nine human subjects were selected initially for this clinical trial, but three were lost to follow-up. So 6 human subjects with bilateral knee Osteoarthritis (12 knees with OA) were studied in this clinical trial. The severity of the Knee Osteoarthritis was grade 2 to 3 of KL Score. After patient selection, Pre-Intra-Articular Injection, a Clinical Examination -General and local Knee Examination was done. Pre-determined functional outcome assessments using KOOS (Knee Injury and Osteoarthritis Scale) Outcome score, validated in Hindi, VAS (Visual Analogue Scale) Score, Kellgren Lawrence Score (KL Score), and Basal Metabolic Index recorded. After an Informed consent, each Knee was injected One Intraarticular Injection of Allogeneic Human umbilical Cord derived Mesenchymal Stem Cell (50x10^6). Cells were provided courtesy MEDITEKFUTURO, for this Clinical Trial. Six subjects with 12 knees were in this clinical trial. The follow-up after the Intra Articular Injection was at 15 ± 3 months and 24 ± 4 months. The first follow-up at 15 ± 3 months was during the first Covid Lockdown, done digitally by remote means, (The First Covid Lockdown in This District of Allahabad, State of Uttar Pradesh, India was from 22nd March 2020 to September 2020). The Lockdown was opened from October 2020 to April 2021. During this window, the second follow up 24 ± 4 months, was done clinically. (The second COVID lockdown was restarted from the end of April to 31st 2021 to the end of May 2021, in this City). The follow up post-injection results at 15 ± 3months and at 24 ± 4 months, recorded importantly for adverse reaction as per WHO guidelines (using CTCAE version 3 of NCI Common Terminology Criteria for Adverse Events, functional parameters did preoperatively were serially recorded at the two follow up period mentioned, and analyzed. The correlation with age and BMI was also analyzed. Results: • Allogenic Human Umbilical Cord derived Mesenchymal Stem Cells used as Intra articular Knee injections w
{"title":"Allogenic Human Umbilical Cord Derived Mesenchymal Stem Cells for Managing Knee Osteoarthritis in Human – A Clinical Trial","authors":"Bhasker Banerji","doi":"10.37191/mapsci-2582-385x-3(5)-082","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-3(5)-082","url":null,"abstract":"Introduction: Human Mesenchymal Stem Cell has been scientifically accepted as a method of managing Osteoarthritis in the Human knee. They can be derived from Autologous Bone Marrow, Adipose Tissue, and less commonly Synovial Cells. However, Allogenic Human Umbilical Cord derived Mesenchymal Stem Cells has recently generated interest because harvesting it is noninvasive, availability easy, the cells relatively younger, have insignificant antigenic markers. A Clinical Trial of Allogeneic Intraarticular Human Umbilical Cord derived Mesenchymal Stem Cells was conducted to assess their efficacy in Osteo Arthritis Human Knees. \u0000\u0000Material and Method: The clinical trials were conducted from my clinic at 72 Tagore Town, Allahabad, UP, India from December 2018 to the third week of March 2021. The period of study was between December 2018 to April 2021. FIRST COVID Lockdown in this city was from 22nd of March 2020 to September 2020. The second Lockdown was from April 2021 to May 2021. Nine human subjects were selected initially for this clinical trial, but three were lost to follow-up. So 6 human subjects with bilateral knee Osteoarthritis (12 knees with OA) were studied in this clinical trial. The severity of the Knee Osteoarthritis was grade 2 to 3 of KL Score. \u0000\u0000After patient selection, Pre-Intra-Articular Injection, a Clinical Examination -General and local Knee Examination was done. Pre-determined functional outcome assessments using KOOS (Knee Injury and Osteoarthritis Scale) Outcome score, validated in Hindi, VAS (Visual Analogue Scale) Score, Kellgren Lawrence Score (KL Score), and Basal Metabolic Index recorded. After an Informed consent, each Knee was injected One Intraarticular Injection of Allogeneic Human umbilical Cord derived Mesenchymal Stem Cell (50x10^6). Cells were provided courtesy MEDITEKFUTURO, for this Clinical Trial. Six subjects with 12 knees were in this clinical trial. The follow-up after the Intra Articular Injection was at 15 ± 3 months and 24 ± 4 months. \u0000\u0000The first follow-up at 15 ± 3 months was during the first Covid Lockdown, done digitally by remote means, (The First Covid Lockdown in This District of Allahabad, State of Uttar Pradesh, India was from 22nd March 2020 to September 2020). The Lockdown was opened from October 2020 to April 2021. During this window, the second follow up 24 ± 4 months, was done clinically. (The second COVID lockdown was restarted from the end of April to 31st 2021 to the end of May 2021, in this City).\u0000\u0000The follow up post-injection results at 15 ± 3months and at 24 ± 4 months, recorded importantly for adverse reaction as per WHO guidelines (using CTCAE version 3 of NCI Common Terminology Criteria for Adverse Events, functional parameters did preoperatively were serially recorded at the two follow up period mentioned, and analyzed. The correlation with age and BMI was also analyzed.\u0000\u0000Results:\u0000\u0000• Allogenic Human Umbilical Cord derived Mesenchymal Stem Cells used as Intra articular Knee injections w","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"57 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134431278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-03DOI: 10.37191/mapsci-2582-385x-3(4)-081
S. Haruta
Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in devastating conditions worldwide. In addition to affecting the respiratory system, COVID-19 affects other systemic organs, and in particular, cardiovascular failure is related to the worsening of symptoms and death. Among these, cardiac insufficiency seems to be an important prognostic factor. Methods and Findings: We reviewed the association between COVID-19 and heart failure by searching Google Scholar and PubMed for reports related to COVID-19 and heart failure and selected those qualitatively and quantitatively established. The presence of heart failure may cause increased susceptibility to SARS-CoV-2 due to an abnormal immune response, which may aggravate COVID-19. In addition, myocardial injury, cytokine storm, endothelial dysfunction, blood coagulation abnormality, and hypoxemia due to respiratory injury may lead to worsening heart failure. Conclusions: Heart failure and COVID-19 are closely related, and their mechanisms are diverse. Multidisciplinary treatment is required to control the progression of cardiac insufficiency, which complicates COVID-19. Further elucidation of the pathology and establishment of efficacious therapy is desirable.
{"title":"Correlation between Coronavirus Disease 2019 and Heart Failure: A Review","authors":"S. Haruta","doi":"10.37191/mapsci-2582-385x-3(4)-081","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-3(4)-081","url":null,"abstract":"Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to the coronavirus disease 2019 (COVID-19) pandemic, which has resulted in devastating conditions worldwide. In addition to affecting the respiratory system, COVID-19 affects other systemic organs, and in particular, cardiovascular failure is related to the worsening of symptoms and death. Among these, cardiac insufficiency seems to be an important prognostic factor.\u0000\u0000Methods and Findings: We reviewed the association between COVID-19 and heart failure by searching Google Scholar and PubMed for reports related to COVID-19 and heart failure and selected those qualitatively and quantitatively established. The presence of heart failure may cause increased susceptibility to SARS-CoV-2 due to an abnormal immune response, which may aggravate COVID-19. In addition, myocardial injury, cytokine storm, endothelial dysfunction, blood coagulation abnormality, and hypoxemia due to respiratory injury may lead to worsening heart failure.\u0000\u0000Conclusions: Heart failure and COVID-19 are closely related, and their mechanisms are diverse. Multidisciplinary treatment is required to control the progression of cardiac insufficiency, which complicates COVID-19. Further elucidation of the pathology and establishment of efficacious therapy is desirable.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125126694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-06-02DOI: 10.37191/mapsci-2582-385x-3(4)-080
Tiyas Sen Dutt
Interstitial lung diseases (ILD) are a group of conditions with varied etiology, clinical presentation, management, outcome and complications. Although studies have described lung cancer as a sequel of ILD, the association of ILD with non-lung malignancies or ILD presenting as a paraneoplastic syndrome of an underlying occult malignancy deserves further study. In this case series, we describe eight patients with an ILD and an associated neoplasm and discuss the different questions raised by this association.
{"title":"Can Interstitial Lung Disease Be A Para-Neoplastic Syndrome?","authors":"Tiyas Sen Dutt","doi":"10.37191/mapsci-2582-385x-3(4)-080","DOIUrl":"https://doi.org/10.37191/mapsci-2582-385x-3(4)-080","url":null,"abstract":"Interstitial lung diseases (ILD) are a group of conditions with varied etiology, clinical presentation, management, outcome and complications. Although studies have described lung cancer as a sequel of ILD, the association of ILD with non-lung malignancies or ILD presenting as a paraneoplastic syndrome of an underlying occult malignancy deserves further study. In this case series, we describe eight patients with an ILD and an associated neoplasm and discuss the different questions raised by this association.","PeriodicalId":325610,"journal":{"name":"Journal of Regenerative Biology and Medicine","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133746608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：